TITLE

Some HIV patients treated during early infection test negative

AUTHOR(S)
Iversen, John
PUB. DATE
July 2004
SOURCE
Bay Area Reporter;7/22/2004, Vol. 34 Issue 30, p19
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
Reports that some HIV patients who received antiretroviral therapy early after infection test negative for HIV. Findings by researchers from the San Francisco, California-based University of California; Implications for HIV care and treatment.
ACCESSION #
14029823

 

Related Articles

  • Comparative Cost-Efficacy Analysis of Darunavir/ritonavir and Other Ritonavir-Boosted Protease Inhibitors for First-Line Treatment of HIV-1 Infection in the United States. Brogan, Anita J.; Mrus, Joseph; Hill, Andrew; Sawyer, Anthony W.; Smets, Erik // HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p133 

    Purpose: A comprehensive study comparing the costs and efficacies of darunavir/ritonavir 800/100 mg qd and the other ritonavir-boosted (/r) protease inhibitors (PIs) recommended for treatment-naïve individuals with HIV-1 infection would help health care decision makers identify the value of...

  • Ambitious plans to roll out ARVs.  // HIV Australia;Mar-May2004, Vol. 3 Issue 3, p5 

    Reports on the plan to launch antiviral treatment programs at several pilot centres for HIV-positive people across Zimbabwe in 2004. Support of the World Health Organization for the program; Cost of a triple generic drug treatment; Reasons for choosing the pilot sites for the program.

  • Oral Glucose Loading for Detection of Mitochondrial Toxicity During HAART in HIV-Infected Patients. Ter Hofstede, Hadewych J. M.; Borm, George F.; Koopmans, Peter P. // Current HIV Research;Oct2007, Vol. 5 Issue 4, p389 

    Nucleoside reverse transcriptase inhibitors used in antiretroviral therapy may cause mitochondrial toxicity. Mitochondrial dysfunction leads to disturbance of the glucose metabolism, resulting in an accumulation of L-lactate. We tested the hypothesis that an oral glucose tolerance test (OGTT)...

  • Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands. Hubben, Gijs A. A.; Bos, Jasper M.; Veltman-Starkenburg, Christa A.; Stegmeijer, Simon; Finnern, Henrik W.; Kappelhoff, Bregt S.; Simpson, Kit N.; Tramarin, Andrea; Postma, Maarten J. // Cost Effectiveness & Resource Allocation;2007, Vol. 5, p15 

    Background: This study compares the costs and effects of a regimen with ritonavir-boosted tipranavir (TPV/r) to a physician-selected genotypically-defined standard-of-care comparator protease inhibitor regimen boosted with ritonavir (CPI/r) in HIV infected patients that were previously exposed...

  • Single Center experience with sides effects of "Triomune®" in Mali. Oumar, A. A.; Dao, S.; Malle, A.; Maiga, A. I.; Fongoro, S.; Diallo, A.; Yombi, J. C. // Journal of Antivirals & Antiretrovirals;2011, Vol. 3 Issue 4, p51 

    Objective: The main objective was to evaluate the sides effects of "Triomune®" among HIV patients followed at Hospital setting. Methods: Our study concerned 68 patients infected by the HIV under antiretroviral treatment with "Triomune®" in infectious diseases service of Point G hospital...

  • Adherence to Antiretroviral Therapy: How Much Is Enough? Gulick, Roy M. // Clinical Infectious Diseases;10/1/2006, Vol. 43 Issue 7, p942 

    The article presents a study on the efficiency of the antiretroviral therapy. It has been stated that the development of effective antiretroviral therapy in the resulted to significant virologic suppression and immune reconstitution and resulted in dramatic reductions in HIV-related morbidity...

  • Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study. Sierra-Madero, Juan; Di Perri, Giovanni; Wood, Robin; Saag, Michael; Frank, Ian; Craig, Charles; Burnside, Robert; McCracken, Jennifer; Pontani, Dennis; Goodrich, James; Heera, Jayvant; Mayer, Howard // HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p125 

    Background: The MERIT study evaluated maraviroc versus efavirenz, both with zidovudine/lamivudine, in treatment-naïve patients with CCR5-tropic (R5) HIV-1. Post hoc analyses previously assessed week 48 outcomes in patients rescreened with R5 virus by a more sensitive tropism assay. Methods:...

  • Impact of Baseline Antiretroviral Resistance Status on Efficacy Outcomes Among Patients Receiving Maraviroc Plus Optimized Background Therapy in the MOTIVATE 1 and 2 Trials. Nelson, Mark; Fisher, Martin; Gonzalez-Garcia, Juan; Rockstroh, Jürgen K.; Weinstein, David; Valdez, Hernan; Mayer, Howard; van der Ryst, Elna; Goodrich, James M.; Dang, Nathalie // HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p145 

    Purpose: The MOTIVATE studies assessed maraviroc with optimized background therapy (OBT) in treatment-experienced patients with R5 HIV-1. This post hoc analysis compared outcomes between patients with and without HIV-1 resistance to ε3 classes of antiretrovirals at screening...

  • Neuropsychiatric Adverse Events With Ritonavir-Boosted Darunavir Monotherapy in HIV-Infected Individuals: A Randomised Prospective Study. Winston, Alan; Fätkenheuer, Gerd; Arribas, Jose; Hill, Andrew; van Delft, Yvon; Moecklinghoff, Christiane // HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p163 

    Background: Protease inhibitor monotherapy is an attractive treatment option for HIV-infected subjects. Data assessing neuropsychiatric events with the use of protease inhibitor monotherapy are sparse. Methods: Clinician- and patient-reported neuropsychiatric events were assessed over 48 weeks...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics